Agile was spun out of
The latest NIH grant supports pre-clinical development of Agile's proprietary Agilyte anti-biofilm molecules for treating lung infections of cystic fibrosis patients. The two-year project will build upon promising data that was generated as a result of a previous NIH Phase I grant award.
The Phase II project will be led by Principal Investigator
Probably the most well-known example of a biofilm is dental plaque - a buildup of bacteria in a form so resilient that it requires periodic scraping in a dentist's office to get rid of it.
That's one of the big problems with biofilms - they're extremely hard to get rid of. And they form in all kinds of places. They resist traditional antibiotics, so they're dangerous when they invade humans, animals and plants.
"These bacteria are sort of like people," explained
"When they communicate well, they find there's safety in numbers. They join together and form these protective clumps. But we break down their communication channels with our technology, so they can't sense each other or indeed the outside world, and they only worry about defending themselves rather than the whole group. That makes them weak and vulnerable."
Cystic fibrosis symptoms include a buildup of thick mucus in the lungs, which can leave them vulnerable to bacterial infection. Though Agile's technology can stop biofilm buildup in everything from plants to battleships, the company has decided to narrow its initial focus to commercializing its cystic fibrosis therapy.
Funding supports important studies
"This award speaks to the success of the Phase I studies and the potential of Agile Sciences' technology to provide a therapeutic advantage in the treatment of lung infections in cystic fibrosis patients," said
"We are particularly grateful to NCBiotech because our original Company Inception Loan of
"Therefore, we have successfully leveraged our original NCBiotech loan with over
Pollard added, "We are also grateful to be collaborating with Dr. Boucher and Dr. Wolfgang, who are leaders in cystic fibrosis research. Their expertise will be instrumental in continuing to advance pre-clinical development of Agile Sciences' therapeutic for cystic fibrosis."
Most Popular Stories
- Businesses, Investors Pressing for Green Policy
- E-scrap Recyclers Find Profits in Upgrades
- Congress Casts a Coy Vote on ISIS War
- At Groupon, Not a Good Deal of Workplace Diversity
- 'The Voice' Sounds Different This Season
- Lower Used-Car Prices Roil the Auto Industry
- Porn Lovers Get a New Search Engine
- Liberty Power Helps USHCC Go Green
- Utah Hosts US Hispanic Chamber of Commerce Meeting
- Investors Fret Yahoo's Future, Stock Dips